Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Green Cross’s HCC Immunotherapy Set For Phase II

This article was originally published in PharmAsia News

Executive Summary

Hoping to expand its presence in the cancer immunotherapy space, South Korea's Green Cross is planning to begin a ground-breaking Phase II clinical program for a novel allogeneic natural killer cell therapy against hepatocellular carcinoma.



Related Companies